Thecurrentlyrecommendedmaintenance doseofclopidogrelis often associated with inadequatep lateleti nhibition, suggesting the need forahigher dose.The aim of this pilot study was to assess thef unctional impacto fah igh (150m g/day) maintenance doseo fc lopidogreli np atientsu ndergoing electivep ercutaneous coronaryi ntervention( PCI).Thisi sap rospective, randomized,plateletfunctionstudy which was performed in electiveP CI patients assignedt ot reatment with eithera7 5m g (n=20) or 150mg(n=20) daily maintenance dose of clopidogrel for30days;afterwards,allpatientsresumed standarddosing.Plateletaggregation was performedusing light transmittance aggregometryf ollowing 20 µMa nd 5 µMa denosine diphosphate (ADP)stimuli 30 days afterrandomization and 30 days after resuming standarddosing. Patientstreatedwith 150 mg/dayclopiKeywords Clopidogrel, platelet, coronarystenting dogrel had lower20µMADP-induced plateletaggregation compared to patients on 75 mg/day(52.1±9% vs.64.0±8%; p<0.001; primaryendpoint).Thedose-dependent effect was confirmedby the absolute and relativei ncrease in plateleta ggregation after resuming standardd osing (p<0.001).N oc hanges were observed in patients randomizedtostandarddosing. Parallelfindings were observed following 5 µMADP stimuli fora ll assessments.A broadvariability in clopidogrel-induced antiplateleteffects was observedi rrespectiveo fd osing. In conclusion, a1 50 mg/daym aintenance doser egimen of clopidogreli sa ssociated with reducedplateletreactivity and enhanced plateletinhibition compared to that achievedwith the currentlyrecommended75 mg/dayinpatientsundergoing electivePCI.
Introduction
Va riability in individual responsivenesst oc lopidogrel is an emerging clinical problem (1) . Numerous factorsaccount forinadequate clopidogrel-induced antiplateleteffects, amongwhich inadequate dosing plays ap ivotal role (1) (2) (3) (4) .D ose finding studies supporting currentlyrecommendeddosagesofclopidogrel were designedtoachieveadegree of platelet inhibition similarto250mg/bidofticlopidine (1, 5) . Importantly,these studies did not takeinto consideration the prothrombotic milleu of high risk subjects, such as those with acute coronarys yndromeso r undergoing percutaneous coronaryi nterventions (PCI). These factorshaverepresented the basis for the continuous debate over the optimaldosing of clopidogrel whichhas emerged in recent years.
Numerousinvestigations have shown thatusing ahigher(≥ 600 mg) than normal (300 mg) clopidogrel loading doseregimen enhances platelet inhibition and improves responseprofiles (3, 4, 6, 7) . Of note, preliminaryfindings have found thata600 mg loading dose of clopidogrel is associatedwith improved clinical outcomesi np atients undergoing PCI (8) (9) (10) . However, the effectsofahigh loading dose of clopidogrel are limitedtothe early phase of treatment and patients mayh avei nadequate clopidogrel-induced antiplateleteffectswhen in the maintenance phase of standard treatment (75 mg/daily) (11) (12) (13) (14) (15) (16) (17) (18) ,suggesting the need for ahighermaintenance dose regimen.This is also supported by the observation thatre-administration of a600 mg loading dose of clopidogrel in patients alreadyo nm aintenance treatment leads to furtherplateletinhibition (19) .However,todate, limited data have beenavailableonclopidogrel-induced antiplateleteffects when ahigh maintenancedose is used (16, 20, 21) . The aim of this study wastoassess the degrees of post-treatment platelet reactivity and platelet inhibition achieved with 150 mg/dayo f clopidogrel compared with 75 mg/day. We hypothesizedt hat a 150 mg/daymaintenance dosing of clopidogrel exerts enhanced antiplateleteffects.
Materials andmethods

Patientpopulation
Patients undergoing electiveP CI withc oronary stenti mplantation were eligiblefor this study.All patients were on chronic treatment with aspirinand were administered a600 mg loading dose of clopidogrel immediately after the interventionalp rocedure. Allp atients were treated with low-dosea spirin (≤ 100 mg/daily).This dose of aspirin waschosen in ordertoreduce the risk of bleeding in patients on duala ntiplatelet therapy ( 22) . Major exclusion criteriaincluded: acute and recent (< 3months) myocardialinfarction; blood dyscrasia;serum creatinine level> 2mg/dL; active bleeding or bleeding diathesis; gastrointestinal bleed within six months; hemodynamic instability; cerebrovascular accidentwithin three months; anymalignancy; concomitant use of otherantithrombotic drugs (oral anticoagulants, dypiridamole, ticlopidine, cilostazol) or non-steroid anti-inflammatoryd rugs; plateletcount <1 00x10 6 /µl; hematocrit <2 5%; liverdisease(bilirubin level>2mg/dL).
Study design
This wasaplateletfunction study with arandomized and prospectivedesign. Patients whohad undergone successfulPCI were eligiblefor randomization. Patients were screened at the post-interventionalc are units of the twop articipating institutions. Using ac omputer-based randomization system, patients were randomized to receive adaily clopidogrel maintenancedose with either 150 mg (two75mgtablets) or 75 mg (one75mgtablets). Thea ssignedc lopidogrel maintenanced ose regimen initiated the morning following the interventional procedurea nd was maintainedfor 30 days, after whichtime plateletfunction wasassessed(study time point 1).Thereafter, allpatients resumedthe standard 75 mg/dailyd ose and plateletf unction wasa ssessed onceagain after 30 days (study time point2). Thelatteranalysis wasperformed in ordertohaveaplateletfunction value while all patients were in the steady state phase of standard dose treatment. It wasperformed at this time pointrather thanearlierafter PCI (e.g.a th ospital discharge) because pharmacokinetic and pharmacodynamic profilesvaryinthe earlyphase of treatment (1) (2) (3) 6) ; therefore plateletfunction valuesobtained maynot reflect the steady state phase.Inaddition, an assessment at alater time pointrather thanshortlyafter PCI would ensurethe absence of interventional procedurerelated factorsonplateletreactivity. Blood sampleswere drawnbyoperatorsblindedtothe patient's treatment assignment. Laboratorypersonnel were alsoblindedto treatment assignments. Patient compliancetoantiplatelet treatment wasa ssessedb yi nterviewa nd pill counting. Af lowd iagram of the studyisillustrated in Fig. 1 .
The study complied with the Declaration of Helsinki and was approvedb yt he locallya ppointed ethics committee.All of the patients gave their informedwrittenconsent. The present study met all requirements for exemption from the InvestigationalNew Drug (IND) regulations [21 CFR 312.2( b)] establishedb yt he Food and Drug Administration. An independent data safety monitoring committee wasinstituted for adjudication of adverse clinicalevents.
Platelet aggregation
Bloodsamples forplateletaggregation were collected froman antecubitalv ein. Samplesw ere collected in tubesc ontaining 3.8% trisodium citrate twotofour hours after antiplatelettherapy intakeand processedwithin one hourafter blood drawing. The first 2-4mlofblood were discarded to avoid spontaneous pla- Angiolillo DJ et al. High clopidogrel dosinginPCI telet activation. Plateletaggregation wasperformed using light transmittanceaggregometry(LTA) according to standard protocols (11) (12) (13) (14) (15) (16) (17) . In brief, platelet aggregation wasa ssessedu sing plateletr ichp lasma (PRP) by the turbidimetric method in a 2-channel aggregometer(Chrono-Log490 Model, Chrono-Log Corp., Havertown, PA ,USA)with the Aggrolink softwarepackage (Chrono-LogCorp., Havertown, PA ,USA)following 5and 20 µMadenosine diphosphate (ADP) stimuli.Samples were centrifugedat120 g for 10 min to recoverplateletrichplasma (PRP) and further centrifugeda t8 50 g for 10 min to recoverp latelet poorplasma (PPP).Plateletconcentration of PRPw as adjusted to 2x10 5 /µlbyadding homologous PPP. Lighttransmission was adjustedto0%with PRP and to 100%for PPPfor each measurement. Aggregation wasmeasured at peak.Inhibition of platelet aggregation (IPA) wasdefinedasthe percent decrease in aggregation obtaineda fter randomization (studyt ime point1 )c ompared with that achievedo nce standard dosing wasr esumed (study time point2 ): IPA( %) =[ (intensity of aggregation at study time point 2) -(intensity of aggregation at study time point 1)]/(intensity of aggregation at study time point 2).The absolute change in plateletaggregation wasdefinedas: (intensity of aggregation at study time point 2) -( intensity of aggregation at study time point 1).A rachidonica cid-induced platelet aggregation wasalso performedinorder to assess responsiveness to aspirin, defined as <20% plateletaggregation following0.5 mg/ ml arachidonic acid stimuli (16) .
Endpoints and samplesizecalculation
The primaryendpoint of the study was20µMADP-induced platelet aggregation 30 days after PCI (studytime point1). We hypothesizedthat a150 mg maintenance dose of clopidogrel would leadt oa2 0% absolute reduction of plateleta ggregation compared to 75 mg (40±18% in patients randomized to 150 mg maintenancedose versus60±18% in patients maintained on 75 mg of clopidogrel). Thus,1 9p atients pergroupw ould be requiredt o provide a9 0% powert od etect as tatistical difference between groups with atwo-sided α-level of 0.05.
Statisticalanalysis
Continuous variablesa re presented as mean ±S D. Categorical variablesa re expressed as frequenciesa nd percentages. Paired and unpaired t-tests were used for intra-group and inter-group comparisons of continuous variables, respectively.D ifferences between categorical variablesw ere assessedb ym eans of the Fisher'se xactt est. Cumulative distribution curvesw ere generated using absolutechangesinplateletaggregation between the 2study time points as variablestoqualitatively describe individual variationsinclopidogrel-induced antiplateleteffects. To assess howthe degree of platelet reactivity affectsdrugresponse achieved with a150mg/dayofclopidogrel, patients were divided into 3groups according to tertilesofADP-induced platelet aggregation while on standard dosing.P atients were defineda s having high, moderate,and lowplateletreactivity from the highestt ol owestt ertile,r espectively ( 3) . Comparisons between groups were made by one-waya nalysis of variance (ANOVA ). Onlypatients whosuccessfullycompleted both visits and were compliant to therapywere consideredfor the analysis. Ap-value <0.05 wasconsideredstatistically significant. Statisticalanalysis wasperformed using aSPSSv13.0software(SPSS Inc. Chicago,IL).
Results
Atotal of 62 patients were eligiblefor the study.Ofthese,16ref-used to participate,withdrew consent or did not completethe two study visits; six patients were excluded duetonon complianceto antiplatelettherapy. Hence, atotal of 40 patients were available for analysis whowere randomized to a150 mg (n=20) or 75 mg (n=20) dailymaintenance dose of clopidogrel.Baseline demographicsand medicaltreatment of the studypopulation aresummarizedinTable 1. There were no differences between the study groups except forage, whichwas higher in patients randomized to standard dosing.Therewas asimilaruse of CYP3A4 and nonCYP3A4metabolizing statins between the twogroups.CYP3A4 metabolizing statins were nota ssociatedw ith clopidogrel-in- ducedantiplatelet effects (data not shown).Therewere no bleeding complications or otherclinical eventsduring the study period. The 150 mg/daymaintenance dose of clopidogrel wasnot associated with anyside effect. Onemonth following randomization (study timepoint 1), patients assigned to a1 50 mg clopidogrel maintenanced ose had significantly lowerplateletaggregation valuesfollowing stimuli with both 20 µM( 52.1±9% vs 64.0±8%; p<0.001; primary endpoint) and 5 µM(38.0±10% vs 46.9±15%; p=0.04) ADP stimuli comparedtopatients randomized to a75mgdose (Fig. 2) . One month after resuming standard treatment (study timepoint 2), patients assigned to the 150 mg dose experienced asignificant increase in plateleta ggregation (p<0.001;T able 2).There were no changes in plateletaggregation between the twostudy time points in patients randomized to standard dosing (Table 2) . A150 mg maintenance dose of clopidogrel wasassociatedwith enhanced IPAf ollowing 20 µM( p<0.001) and 5 µM( p=0.05) ADP stimuli,w hile no changes were observedi np atients on standard dosing (Fig. 3) .All patients were responsive to aspirin (arachidonic acidinducedplateletaggregation <20% in all patients).
A150 mg/daymaintenance dose of clopidogrel wasassociated with enhanced antiplateleteffects, although abroad individualv ariation in the degree of antiplatelete ffectsa chieved,a s shown by the cumulativedistribution curvesofabsolutechanges in 20 and 5 µMADP-induced platelet aggregation (Fig. 4) ,was observed. In patients treated with ahigh maintenancedose, 50% (n=10) and 60% (n=12) had >10% absolute change in 20 and 5 µMADP-induced platelet aggregation, respectively.P atients with high plateletreactivity while on astandard 75 mg/daydose, defined as the upper tertileofADP-induced platelet aggregation in the steady state phase of treatment, hadgreater responsiveness to 150 mg/daycompared to patients with moderate and lowplateletreactivity (Fig. 5) .
Discussion
In this randomized prospectivestudy we confirmed the hypothesis that ahigh maintenancedose (150 mg/daily) of clopidogrel in patients undergoing PCI with stent implantation is associated with asignificantly lowerpost-treatment plateletreactivity compared to as tandard dosage( 75 mg/daily). The dose-dependent effect of clopidogrel wasalso supportedbythe increase in platelet aggregation when standard dosing wasresumed. However, despite an overallimprovement in post-treatment plateletreactivity and platelet inhibition amongp atients randomized to a high maintenanced ose of clopidogrel,t hese effects were not homogeneous and antiplateleteffectsremained broadly variable irrespective of the dosage used.
Va riability in individual responsivenesstoclopidogrel is an emerging clinical problem(1). Inadequate clopidogrel-induced antiplatelete ffectsh aveb een associatedw ith ar ecurrence of In fact,h igh loading doses (≥ 600mg) acceleratea nd enhance plateletinhibition comparedtoastandard 300mgloading dose (3, 4, 6, 7) . Of note, a600 mg loading dose has shown to improve short-term clinical outcomes (8) (9) (10) . These clinicalbenefits are primarily drivenbyareduction in peri-procedural myocardialinfarction rates.These findings areinline with the biological effectsofhigh clopidogrel dosing, whichprevail during the first 24-48hours after its administration (1, 3) . However, inadequate clopidogrel-induced antiplatelete ffectsm ay be present in the maintenance phase of therapy (11) (12) (13) (14) (15) (16) (17) (18) . This is of concernsince patients relyontheir dailymaintenance dose forlong-term prevention of ischemic events. Most recently,inadequate plateletinhibition determinedinpatients while in their maintenancephase of clopidogrel treatment hasb een associatedw ith poorl ongtermclinical outcomes (17) (18) . Since age is avariable thatmay contribute to differences in drug metabolism, it maybeargued that this mayh avei nfluencedc lopidogrel-induced antiplatelet effectsinthe present study since patients randomized to 75 mg dosing were slightlyolderthan those assigned to 150 mg. Nevertheless, we did not find anydifferences in plateletaggregation between the twog roups once theyh ad both resumeds tandard dose treatment. Thep otential for using a1 50 mg/daym aintenance dose of clopidogrel has recentlybeen raisedinthe updated2005 ACC/ AHA/SCAIguidelines on PCI (35) . In fact,anew classIIb indication with alevel of evidenceCstatesthat in patients in whom stent thrombosis mayb ec atastrophic or lethal, plateleta ggregation studiesmay be consideredand the dose of clopidogrel increased to 150 mg perday if less than50% inhibition of platelet aggregation is demonstrated (35) .Although this approach is currentlyusedinclinical practice, there is limiteddatatosupportit. To date,o nlyo ne study has evaluatedt he impact of a1 50 mg maintenance dose of clopidogrel in patients undergoing PCI (20). In this study, a150 mg dailymaintenance dose of clopidogrel wasa ssociatedw ith as ignificant reduction in post-treatment plateletreactivity 30 days followingPCI compared to 75 mg. However, in contrasttoour investigation, in this report platelet function wasonlyassessedatasingle time point, thus impeding to assess changes in plateleta ggregation compared to standard dose treatment and to identifyp atients in whom high dosing is most biologicallye ffective. In ourc urrent study,w e confirm the impact on post-treatment plateletr eactivity of 150mg/dayofclopidogrel post-PCI.Inaddition, we demonstrate the dose-dependent effect of clopidogrel by showing enhanced changes in plateletaggregation over time oncepatients resumed standard dosing.S imilarfindings were observedi nt he OPTI-MUS (Optimizing anti-PlateletTherapyI nd iabetesM ellitUS) study ( 16) . However, this studyw as notp erformed in patients undergoing PCI and in whicha150 mg maintenance dose was utilizedselectivelyindiabetic patients presenting with suboptimalc lopidogrel-induced antiplatelete ffectsw hile on chronic treatment (16) .E nhanced plateleti nhibition using clopidogrel 150mgwas also shown in anon-selective cohortofpatients with low-responsiveness to standard dosing while in the maintenance phase of treatment (21) . Indeed,n one of the studies available testing a150 mg maintenance dose of clopidogrel,including the present, were designedtoevaluate the safety and efficacyofthis dose regimen. The safety and efficacyofhigh clopidogrel dosing, whichincludesa150 mg/daymaintenance dose,iscurrently being evaluatedinthe CURRENT/OASIS-7 (Clopidogrel optimalloading dose Usage to ReduceRecurrentEveNTs/Optimal Antiplatelet Strategyfor InterventionS) trial (1) .
Numerous studies have demonstrated that thereisgreat interindividual variability in clopidogrel-induced antiplateleteffects achieved when using standard treatment regimens (1-3), suggesting thatthis phenomenon could be overcome by increasing the dose (3, 4, 6, 7) . Although high loading dose regimens reduce the levels of plateletreactivity,this does not narrowthe range of antiplateleteffectsachieved,which persist highlyvariable (3, 4, 6, 7, 36) . Pharmacokinetic profileso fc lopidogrel, and nott he potencyo fi ts activem etabolite pers e, account fort he broad range of variation in clopidogrel-induced antiplatelete ffects (37) .N ew P2Y 12 receptor antagonists( prasugrel, AZD6140, cangrelor) characterized by moref avorablep harmacokinetic profiles have beena ssociatedw ith moreh omogenous pharmacodynamic effects (1, 38) . It is currentlyb eing investigated whethr the morepotent plateletinhibition and lowervariation in antiplateleteffectsachieved with these novelagents also translate into better clinicaloutcomes (1, 38) .
Abroad rangeofinter-and intra-individual variability in antiplateleteffectswere observed in the present study when using a higher thanstandard maintenancedose of clopidogrel.However, we did showthat the antiplateleteffectsachieved with a150 mg/ daym aintenance dose regimen were morep ronounced in patients with high plateletr eactivity while on 75 mg/day, while these were less marked in patients with lowerdegrees of platelet reactivity.Although the cut-off value of post-treatment platelet reactivity to define when standard dose clopidogrel is less effective is not established, maximalp lateleta ggregation following 20 µMA DP stimulig reater than5 0% identified the majority (~90%) of patients developingadverse ischemic eventspost-PCI (26) .Accordingly,inthe OPTIMUS study this cut-offvalue was used as ac riterion for randomization with 150 mg clopidogrel (16) .Inthe current study acut-offv alue wasnot used as acriterion for randomization and in which, similart oI SAR-CHOICE 2, all patients were randomized irrespective of their plateletfunction value (20). In particular, we observedthat patients with maximal plateletaggregation following20µMADP stimuligreater than68% benefittedthe most from high maintenancedose treatment. However, in patients with plateletfunction belowthis value,the magnitude of the changes were less notable, suggesting this as ac ut-offv alue to be consideredf or 150 mg clopidogrel maintenancedosing. It is important to note that although patients with lowerr esponsivenesst os tandard dose clopidogrel benefit most from ahigherdosage,the degree of plateletinhibition achievedinthese patients using 150 mg still does not yield that of patients with adequate response to standard dosing (21, 39) . This suggests that thereisaneedfor alternative and morepotent antiplateletagents in these patients (1, 38) . Indeed, it maybeargued that in the present study effectiveness to standardclopidogrel dosing wasassessed30daysafter the randomization phase wascompleted,questioning the idealand practical timepoint to performthis assessment. Although the assessment of plateletfunction following PCI, before hospital discharge, has been shown to be associatedwith adverseoutcomes (26) ,further studies arewarrantedtofind out if this representsanidealtime pointtoestablish whether or nottouse more aggressive antiplateletdrugregimens (40) (41) .
In conclusion,a1 50 mg/daym aintenance dose regimen of clopidogrel is associatedwith reduced platelet reactivity and enhanced platelet inhibition compared to thata chieved with the currentlyrecommended75mg/dayinpatients undergoing elective PCI.Despite the enhanced clopidogrel-induced antiplatelet effectsa chieved with ah igh maintenanced ose of clopidogrel, these were nothomogeneous and were morepronounced in patients with high plateletreactivity while on standard dosing.Ongoing studies areevaluating the safety and efficacyofhigh dose regimens of clopidogrel and of newergeneration P2Y 12 receptor antagonistswith morepotent antiplateleteffects.
Study limitations
Plateletfunction before clopidogrel treatment wasnot assessed. Therefore, our study cannot determine the degree of responsivenessa chieved with regard to its pre-thienopyridine treatment status. However, the objectives of this studywere to assess how plateletfunction profiles using ahigh maintenancedose of clopidogrel comparewith thoseachieved when using astandard dose. Thedegree of posttreatment plateletreactivity waschosen as the primaryendpoint as this has beenshown to be abetterdeterminant of ischemic risk thanresponsiveness (1, (40) (41) .
